Facebook Linkedin Mail Twitter Youtube
Facebook Linkedin Mail Twitter Youtube

Tag: SEAL IT

Galaxy Therapeutics completes enrolment of primary cohort in pivotal SEAL IT...

Galaxy Therapeutics has today announced completed enrolment of the primary cohort of patients in its SEAL IT investigational device exemption (IDE) trial. The trial's primary...
NeuroNews

Write to us
Editor: Jamie Bell [email protected]
Advertising: Abbie Richardson [email protected]


United Kingdom:

BIBA Medical, Europe
526 Fulham Road, Fulham, London, SW6 5NR
TEL: +44 (0)20 7736 8788
Email: [email protected]

United States:

BIBA Medical, North America
155 North Wacker Drive, Suite 4250, Chicago, IL 60606
TEL: +1 949 723 9309
Email: [email protected]

Terms and Conditions | Privacy Policy

Facebook Linkedin Mail Twitter Youtube